Please find attached transcript of the Investor Conference call for Q1FY27 held on July 30, 2026

AI summary - Q1FY27 revenue increased 13% y-y to INR4,031 Cr; EBITDA margin improved 250 bps to 26.3% - Domestic revenue ex-Consumer Healthcare up 11% y-y; chronic share rose to 40%, targeting 50% medium term - Chronic portfolio grew 15.8% y-y; acute portfolio recovered to 10.9% growth - International business grew 29% y-y; BSV segment grew 21% with domestic at 17% and international at 25% - Gross margin expanded 230 bps y-y to 72.8%; EBITDA margin gain driven by margin expansion and operating leverage - Effective tax rate rose to 25.4% due to new tax regime; PAT grew 29.1% y-y to INR574 Cr - Net debt reduced to INR3,377 Cr; net debt/EBITDA at 0.9x; capex at 4.9% of revenue - Management cautious on GLP-1 launch due to hypercompetition and price war; focusing on therapy approach - Consumer Healthcare growth soft at 3.8% due to cash and carry business discontinuation; expecting high single-digit to double-digit growth from Q2 - Attrition and vacancies normalized after reorganization; prescription leadership sustained at 15.2% share